Literature DB >> 27141369

Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer.

J H Park1, D C McMillan2, J Edwards3, P G Horgan2, C S D Roxburgh2.   

Abstract

The aim of the present study was to compare the clinical utility of two measures of the inflammatory cell infiltrate - a H&amp;E-based assessment of the generalized inflammatory cell infiltrate (the Klintrup-Mäkinen (KM) grade), and an immunohistochemistry-based assessment of combined CD3+ and CD8+ T-cell density (the "Immunoscore"), in conjunction with assessment of the tumor stroma percentage (TSP) in patients undergoing resection of stage I-III colorectal cancer (CRC). Two hundred and forty-six patients were identified from a prospectively maintained database of CRC resections in a single surgical unit. Assessment of KM grade and TSP was performed using full H&amp;E sections. CD3+ and CD8+ T-cell density was assessed on full sections and the Immunoscore calculated. KM grade and Immunoscore were strongly associated (p < 0.001). KM grade stratified cancer-specific survival (CSS) from 88% to 66% (p = 0.002) and Immunoscore from 93% to 61% (p < 0.001). Immunoscore further stratified survival of patients independent of KM grade from 94% (high KM, Im4) to 60% (low KM, Im0/1). Furthermore, TSP stratified survival of patients with a weak inflammatory cell infiltrate (low KM: from 75% to 47%; Im0/1: from 71% to 38%, both p < 0.001) but not those with a strong inflammatory infiltrate. On multivariate analysis, only Immunoscore (HR 0.44, p < 0.001) and TSP (HR 2.04, p < 0.001) were independently associated with CSS. These results suggest that the prognostic value of an immunohistochemistry-based assessment of the inflammatory cell infiltrate is superior to H&amp;E-based assessment in patients undergoing resection of stage I-III CRC. Furthermore, assessment of the tumor-associated stroma, using TSP, further improves prediction of outcome.

Entities:  

Keywords:  Colorectal cancer; tumor inflammatory cell infiltrate; tumor microenvironment; tumor stroma

Year:  2016        PMID: 27141369      PMCID: PMC4839333          DOI: 10.1080/2162402X.2015.1098801

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  28 in total

1.  Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria.

Authors:  Natalie Turner; Hui-Li Wong; Arnoud Templeton; Sagarika Tripathy; Te Whiti Rogers; Matthew Croxford; Ian Jones; Mathuranthakan Sinnathamby; Jayesh Desai; Jeanne Tie; Susie Bae; Michael Christie; Peter Gibbs; Ben Tran
Journal:  Int J Cancer       Date:  2015-09-02       Impact factor: 7.396

2.  The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.

Authors:  J H Park; C H Richards; D C McMillan; P G Horgan; C S D Roxburgh
Journal:  Ann Oncol       Date:  2014-01-23       Impact factor: 32.976

3.  Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host.

Authors:  James H Park; David G Watt; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan
Journal:  Ann Surg       Date:  2016-02       Impact factor: 12.969

4.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

5.  Neutrophil extracellular traps promote differentiation and function of fibroblasts.

Authors:  Akrivi Chrysanthopoulou; Ioannis Mitroulis; Eirini Apostolidou; Stella Arelaki; Dimitrios Mikroulis; Theocharis Konstantinidis; Efthimios Sivridis; Maria Koffa; Alexandra Giatromanolaki; Dimitrios T Boumpas; Konstantinos Ritis; Konstantinos Kambas
Journal:  J Pathol       Date:  2014-05-19       Impact factor: 7.996

6.  The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy?

Authors:  Ewout F W Courrech Staal; Michel W J M Wouters; Johanna W van Sandick; Marijn M Takkenberg; Vincent T H B M Smit; Jan M C Junggeburt; Juliette M J Spitzer-Naaykens; Tom Karsten; Henk H Hartgrink; Wilma E Mesker; Rob A E M Tollenaar
Journal:  Eur J Cancer       Date:  2010-01-13       Impact factor: 9.162

7.  Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis.

Authors:  L De Smedt; J Lemahieu; S Palmans; O Govaere; T Tousseyn; E Van Cutsem; H Prenen; S Tejpar; M Spaepen; G Matthijs; C Decaestecker; X Moles Lopez; P Demetter; I Salmon; X Sagaert
Journal:  Br J Cancer       Date:  2015-06-11       Impact factor: 7.640

Review 8.  Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis.

Authors:  Z Mei; Y Liu; C Liu; A Cui; Z Liang; G Wang; H Peng; L Cui; C Li
Journal:  Br J Cancer       Date:  2014-02-06       Impact factor: 7.640

9.  Comment on 'Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis'.

Authors:  J H Park; C S D Roxburgh; D C McMillan
Journal:  Br J Cancer       Date:  2014-10-28       Impact factor: 7.640

10.  The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage.

Authors:  Wilma E Mesker; Jan M C Junggeburt; Karoly Szuhai; Pieter de Heer; Hans Morreau; Hans J Tanke; Rob A E M Tollenaar
Journal:  Cell Oncol       Date:  2007       Impact factor: 6.730

View more
  11 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  CD103+ cells at the forefront of anticancer immunity.

Authors:  Claire Vanpouille-Box; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-07-31       Impact factor: 8.110

3.  Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer.

Authors:  Katarzyna Jakubowska; Wojciech Kisielewski; Luiza Kańczuga-Koda; Mariusz Koda; Waldemar Famulski
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

Review 4.  Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer.

Authors:  Catherine R Hanna; Séan M O'Cathail; Janet Graham; Richard Adams; Campbell S D Roxburgh
Journal:  J Immunother Precis Oncol       Date:  2021-03-26

5.  Predictive value of different proportion of lesion HLA-G expression in colorectal cancer.

Authors:  Rui-Li Zhang; Xia Zhang; Shan-Shan Dong; Bing Hu; Qiu-Yue Han; Jian-Gang Zhang; Wen-Jun Zhou; Aifen Lin; Wei-Hua Yan
Journal:  Oncotarget       Date:  2017-11-18

6.  Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer.

Authors:  J H Park; H van Wyk; C S D Roxburgh; P G Horgan; J Edwards; D C McMillan
Journal:  Br J Cancer       Date:  2017-04-20       Impact factor: 7.640

7.  Prognostic Value of Tumor-Stroma Ratio in Rectal Cancer: A Systematic Review and Meta-analysis.

Authors:  Yuzhou Zhu; Zechuan Jin; Yuran Qian; Yu Shen; Ziqiang Wang
Journal:  Front Oncol       Date:  2021-05-26       Impact factor: 5.738

8.  Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.

Authors:  Stéphanie M Zunder; Gabi W van Pelt; Hans J Gelderblom; Christoph Mancao; Hein Putter; Rob A Tollenaar; Wilma E Mesker
Journal:  Br J Cancer       Date:  2018-05-14       Impact factor: 7.640

9.  Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content.

Authors:  Tessa P Sandberg; Jan Oosting; Gabi W van Pelt; Wilma E Mesker; Rob A E M Tollenaar; Hans Morreau
Journal:  Oncotarget       Date:  2018-07-31

10.  An isoform of AIF1 involved in breast cancer.

Authors:  Ferial Amira Slim; Geneviève Ouellette; Kaoutar Ennour-Idrissi; Simon Jacob; Caroline Diorio; Francine Durocher
Journal:  Cancer Cell Int       Date:  2018-10-22       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.